Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). Tolerability & Disease Control Rate: Shows...
Hence then, the article about senhwa biosciences announces positive clinical data from phase 1 expansion trial of silmitasertib cx 4945 in the treatment of basal cell carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma )
Also on site :
- Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
- Reported tornado rips roofs off multiple homes in central Illinois
- Heidi Klum ditches bikini top to cozy up to husband Tom Kaulitz during St. Barths vacation